Australia's most trusted source of pharma news
Tuesday, 20 March 2018
Lost Your Access?
Who's best for MA CEO?
Observers say new boss will need a special blend of skills, so who fits the mould?
Lundbeck joins neuro jockeying
Pfizer may have backed out but the neuroscinece market is busy none-the-less.
Alexion looks beyond Soliris
Prepping for expiry of its only PBS-listed drug.
GSK offers cash for innovation
Brings competition to flush out new medicines to Aust.
Aussies top sleep drug users
Highest use of prescription insomnia treatments among 13 major countries.
MA in rebate talks with Hunt
Will join this week's sector-wide meeting on deeds of agreement changes.
Roche jets in new comms boss
Senior corporate affairs appointment comes from inside own ranks.
Huge pay hike for Pfizer boss
Millions extra persuade CEO to stick to US giant, but Allergan equivalent paid more.
Pfizer plant's 'emotional' end
: End of an era for West Ryde location.
Another CEO exit rocks MA
: Catelin returning to UK after only 18 months in top job.
The rise and rise of MSD
: Biggest PBS benefits surge in a decade - and it's not just
Breast cancer probe put off
Committee cites 'immature' utilisation data, will look again in 2020.
MSD wins IO fast track
Checkpoint inhibitor race shifts gears.
Media pushes Hunt on Keytruda
Put on the spot over lymphoma listing but MSD optimistic.
Janssen's new biologic approved
Will challenge Humira for lucrative psoriasis market, plus new indication for Novartis drug.
Keytruda chases 14th indication
Cervical cancer next on the IO blockbuster's list.
What's behind MA's CEO problem?
Board needs to ask questions over vanishing secretariat leaders.
Events & Conferences
© 2003 - 2018 Lush Media
Pharma in Focus
Jolly Good Design